Analysis of clinical characteristics and prognosis of 235 pancreatic neuroendocrine tumors underwent Sunitinib treatment
10.3760/cma.j.cn112152-20190630-00402
- VernacularTitle:235例接受舒尼替尼治疗的胰腺神经内分泌瘤患者的预后因素分析
- Author:
Jianming XU
1
;
Heteng CUI
;
Ru JIA
;
Chuanhua ZHAO
;
Ping ZHAO
Author Information
1. 解放军总医院第五医学中心消化肿瘤科，北京 100071
- Keywords:
Pancreatic neuroendocrine tumors;
Clinical characteristics;
Prognosis;
Sunitinib
- From:
Chinese Journal of Oncology
2021;43(3):324-328
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical characteristics, treatment, and prognostic factors of pancreatic neuroendocrine tumors (pNETs) patients treated with Sunitinib.Methods:The clinical data of pNETs patients from Pfizer Drug Assistance Program of Cancer Foundation of China from April 2013 to November 2017 were retrospectively analyzed. Follow-up and statistical analysis were performed.Results:A total of 235 patients were enrolled, the patients′ overall survival time was between 4 and 252 months, the 3-years and 5-years survival rates were 73.8% and 60.8%, respectively. Univariate analysis showed that factors such as age, Ki-67 index and surgery were associated with the 3-years survival rates of pNETs patients ( P<0.05). Multivariate analysis demonstrated that the age, Ki-67 index and surgery were independent prognostic factors for pNETs patients ( P<0.05). For patients with liver metastases, univariate analysis revealed that surgery was associated with prognosis ( P<0.05). The 5-years survival rate of 124 patients with extending usage of Sunitinib was 53.3%. Conclusion:PNETs are rare tumors with atypical clinical symptoms and the patients often have metastasis at the initiate diagnosis. The age, Ki-67 index and surgery are associated with the prognosis of pNETs patients.
